1cP-MiPLA

1cP-MiPLA is a semisynthetic psychedelic of the lysergamide class that first emerged as a novel designer drug around 2020. It is a structural analog of MiPLA and is suspected to act as a prodrug for that compound, though insufficient data currently exists to confirm this relationship. As a research chemical with limited documented human use, its safety profile and pharmacological properties remain poorly characterized.

Also known as: 1‑cyclopropionyl‑MiPLA

Classification

Chemical: Lysergamide
Psychoactive: Psychedelic

Effects

Pupil Dilation
Stimulation
Nausea
Difficulty Urinating
Spontaneous Bodily Sensations
Physical Euphoria
Euphoria
Time Distortion
Motivation Enhancement
Machinescapes
Depth Perception Distortions
Thought Acceleration
Drifting
Tracers
Color Enhancement
Auditory Hallucination
Auditory Distortion
Pattern Recognition Enhancement

Routes of Administration

Oral

Dosage

Heavy: 400+ µg
Light: 100 – 150 µg
Common: 150 – 200 µg
Strong: 200 – 250 µg
Threshold: 40–60 µg

Duration

Onset: 0.33-0.67 h
Comeup: 0.75-1.5 h
Peak: 1.5-3 h
Offset: 3.5-6 h
After Effects: 6-12 h
Total Duration: 5-8 h

Sublingual

Dosage

Heavy: 400+ µg
Light: 70–110 µg
Common: 110–250 µg
Strong: 250–400 µg
Threshold: 40 µg

Duration

Onset: 0.25-0.67 h
Peak: 1.25-2.75 h
Offset: 3-6 h
After Effects: 6-12 h
Total Duration: 5-8 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu